➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
McKesson
Johnson and Johnson
Colorcon

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Follitropin alfa/beta - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for follitropin alfa/beta
Tradenames:5
Patents:9
Applicants:2
BLAs:6
Suppliers: see list2
Recent Clinical Trials: See clinical trials for follitropin alfa/beta
Recent Clinical Trials for follitropin alfa/beta

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 2
Instituto Valenciano de Infertilidade de LisboaPhase 4
Ferring PharmaceuticalsPhase 2

See all follitropin alfa/beta clinical trials

Company Disclosures: US Patents for follitropin alfa/beta

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23   Start Trial Genzyme Corporation (Cambridge, MA) 2015-06-16 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23   Start Trial Akzo Nobel, N.V. (Arnhem, NL) 2017-01-15 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23   Start Trial Ares Trading S.A. (Aubonne, CH) 2018-07-23 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23   Start Trial Ares Trading S.A. (Aubonne, CH) 2018-07-23 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 002 2004-03-23   Start Trial Genzyme Corporation (Cambridge, MA) 2015-06-16 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 002 2004-03-23   Start Trial Akzo Nobel, N.V. (Arnhem, NL) 2017-01-15 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 002 2004-03-23   Start Trial Ares Trading S.A. (Aubonne, CH) 2018-07-23 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for follitropin alfa/beta

These patents were identified by searching patent claims

Supplementary Protection Certificates for follitropin alfa/beta

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
60004 Netherlands   Start Trial PRODUCT NAME: RECOMBINANT HUMAAN FOLLIKELSTIMULEREND HORMOON; REGISTRATION NO/DATE: EU/1/95/001/001 - EU/1/95/001/016 19951020
2010 00022 Denmark   Start Trial PRODUCT NAME: REKOMBINANT FSH-CTP
C/GB01/022 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN LUTEINISING HORMONE; REGISTERED: UK EU/1/00/155/001-006 20001129
5/1996 Austria   Start Trial PRODUCT NAME: REKOMBINANTES HUMANES FOLLIKELSTIMULIERENDES HORMON
C0010 Belgium   Start Trial PRODUCT NAME: FOLLITROPINE ALPHA; NAT. REGISTRATION NO/DATE: EU1/95/001/001 19951020; FIRST REGISTRATION: FI 11529 19940815
2010 Austria   Start Trial PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
C00034 Luxembourg   Start Trial PRODUCT NAME: FSH RECOMBINANTE (RFSH) COMPRENANT LA SIALYLATION 2,3 ET LA SIALYLATION 2,6 OU 80% OU PLUS DE LA SIALYLATION TOTALE EST LA SIALYLATION 2,3 ET OU DE 5% A 20% DE LA SIALYLATION TOTALE EST LA SIALYLATION 2,6 ; ENPARTICULIER LA FOLLITROPINE DELTA; AUTHORISATION NUMBER AND DATE: EU/1/16/1150 20161214
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Medtronic
Mallinckrodt
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.